Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Palatin’s Oral Obesity Drug Shows Remarkable Results: The Hidden Gem in the Weight Loss Race

Palatin Technologies (OTCQB: PTNT) (NYSE: PTN) may have just positioned itself as a serious contender in the rapidly expanding obesity treatment market with impressive new preclinical data for its oral MC4R agonist PL7737. The results, announced today, demonstrate both rapid weight loss as a standalone therapy and enhanced effects when combined with GLP-1 medications like tirzepatide.

In an industry dominated by injectable GLP-1 treatments from pharmaceutical giants like Novo Nordisk and Eli Lilly, Palatin's oral small molecule approach could represent a significant breakthrough for patients seeking alternatives.

Striking Results in Just Four Days

The preclinical study evaluated PL7737 in a diet-induced obesity (DIO) rat model, with results that should catch investors' attention:

After just four days of treatment, high-dose PL7737 alone produced 10% weight loss, doubling the 5% seen with tirzepatide alone. When combined, high-dose PL7737 plus tirzepatide achieved an impressive 15% weight loss - suggesting a powerful synergistic effect.

"The rapid and significant weight loss seen with oral PL7737, both as monotherapy and in combination with tirzepatide in this established animal model, is impressive and suggests the potential for meaningful weight reduction in humans," said Carl Spana, Ph.D., President and CEO of Palatin.

Why This Matters for Investors

While GLP-1 medications have transformed obesity treatment, they come with significant drawbacks: high costs, side effects leading to discontinuation, and weight regain when treatment stops. Palatin's melanocortin approach targets a completely different pathway (MC4R) that directly influences appetite and energy regulation in the brain.

This creates multiple market opportunities:

  • As a standalone oral treatment option
  • In combination with GLP-1s for enhanced weight loss
  • For weight maintenance following GLP-1 therapy
  • For specialized conditions like hypothalamic obesity

What's particularly intriguing is that Palatin appears to be less than 18 months behind the only other major player in the MC4R space - Rhythm Pharmaceuticals, which currently sports a market cap around $5.8 billion. Yet Palatin trades at a fraction of that valuation.

The Hypothalamic Obesity Opportunity

While the general obesity market is enormous, Palatin is also targeting hypothalamic obesity - a rare, severe form of obesity caused by damage to the brain's appetite control center. This condition affects patients who have undergone surgery or radiation for brain tumors, particularly craniopharyngioma.

Patients with hypothalamic obesity experience uncontrollable hunger and rapid weight gain that's resistant to conventional interventions. With no FDA-approved treatments specifically for this condition, Palatin's PL7737 could potentially address a significant unmet need.

The FDA has already granted orphan drug designation to PL7737 for leptin receptor deficiency-related obesity, another rare genetic disorder affecting the melanocortin pathway.

Development Timeline and Catalysts

Investors looking at Palatin should note several upcoming catalysts:

  • IND submission planned for Q4 2025
  • Phase 1 SAD/MAD clinical trial initiation in late 2025, including hypothalamic obesity patients
  • Initial clinical data expected in the first half of 2026

Dr. Spana added, "Palatin is developing a strong pipeline of novel MC4R agonists to treat obesity. Unlike incretin-based therapies, MC4R agonists offer a unique mechanism of action... Our deep expertise in melanocortin research allows us to efficiently advance both oral PL7737 and a long-acting peptide candidate, providing flexibility to target both general obesity and rare forms of the disease."

Investment Perspective

For investors seeking exposure to the booming obesity market beyond the established players, Palatin may present a unique opportunity. The company has already demonstrated clinical success with its melanocortin platform through positive Phase 2 results combining bremelanotide with tirzepatide earlier this year.

The global weight management market is projected to reach nearly $900 billion by 2035, with obesity medications expected to capture an increasing share. For a small biotech with promising data and a differentiated approach, Palatin could be positioned for significant growth if clinical trials confirm these preclinical findings.

While still in early stages of development, today's preclinical data suggests Palatin's melanocortin approach could eventually carve out a meaningful position in this explosive market. Investors might want to keep a close eye on this emerging player as it advances toward clinical trials.

 

 

Recent News Highlights from Palatin

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

 

 

Disclaimer & Disclosure: This content is a paid advertisement. The Authoer, Wall Street Wire, has received compensation from Palatin Technologies Incfor promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available wallstwire.ai/disclosures

 

Media Contact
Company Name: Wall Street Wire
Contact Person: Content Staff
Email: Send Email
Country: United States
Website: wallstwire.ai

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.